Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shield wins Axis shareholders with better offer:

This article was originally published in Clinica

Executive Summary

Shield Diagnostics has been forced to improve its offer for homocysteine test rival, Axis Biochemicals, in order to secure the support of two key investors in the Norwegian company. The one-for-one share offer has been modified to 1.25 Shield shares for every one Axis. This changes the ownership ratio of Shield from 62% to 57%. The improved offer placates Tharald Brovig and venture capital company Mosvold-Farsund, who together own 13.7% of Axis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT077666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel